Iconovo AB carries out a directed share issue and raises SEK 60 million before issue costs
The Board of Directors of Iconovo AB ("Iconovo" or the “Company") has utilised the authorisation received at the AGM on 15 May 2019 and resolved on a…
PRESS RELEASE, 19 November 2019
Granted ICOres patent in Japan
The Japan Patent Office has granted a patent regarding Iconovo’s dry powder inhaler, ICOres. Iconovo has already several…
Iconovo met innovation companies at BIO-Europe
At last week’s BIO-Europe conference, BioStock caught Iconovo’s Roger Lassing, VP of Business Development, between a series of interesting meetings.
We…
Iconovo’s new collaboration aims to optimise current inhalation products
British CrystecPharma begins a collaboration with the Swedish inhaler developer Iconovo with the aim of formulating new innovative compounds for use in…
PRESS RELEASE, 5 November 2019
Iconovo and CrystecPharma to collaborate in development of innovative inhaler products
Iconovo today announced that it signed a Letter of Understanding…
MARKET ANALYS OF ICONOVO BY ERIK PENSER BANK (ONLY IN SWEDISH)
Analys från Penser access:
Iconovo - Tar klivet in i USA genom ny plattform. Läs mera här
PRESS RELEASE, 25 October 2019
Iconovo AB (publ) makes a significant investment in the development of a new inhalation platform
Iconovo AB (publ) announced today that the company has…
ICONOVO’S WEAPON IN THE FIGHT AGAINST ASTHMA
Asthma has long been a significant global health issue and the problem only appears to grow. This summer a report from Asthma UK showed a marked increase…
CLINICAL PROGRESS UPS THE VALUE OF ICONOVO’S FLAGSHIP PROJECT
Lund based Iconovo did not sit still during the summer, instead the company released the biggest news of the year thus far. in mid-July, Iconovo announced…
MARKET ANALYS OF ICONOVO BY ERIK PENSER BANK (ONLY IN SWEDISH)
Positivt kliniskt resultat ger höjd riktkurs. Läs mera här
